Skip to main content
Log in

Lopinavir/Ritonavir

A Review of its Use in the Management of HIV Infection

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

Coformulated lopinavir/ritonavir (Kaletra®) is a boosted protease inhibitor (PI) containing lopinavir and low-dose ritonavir. It is approved for use in combination with other antiretroviral drugs for the treatment of HIV infection in adults, adolescents and children aged ≥6 months (in the US) or ≥2 years (in the EU).

Lopinavir/ritonavir-based antiretroviral therapy (ART) is generally well tolerated and has shown durable virological efficacy in clinical trials in ART-naive and -experienced patients with virological failure. Lopinavir/ritonavir is one of the preferred PIs for first-line treatment of HIV infection in adults, adolescents and children, according to US and British guidelines, reflecting its comparatively better virological efficacy than nelfinavir and low incidence of de novo resistance during long-term treatment. Lopinavir/ritonavir-based treatment may produce a more effective virological response than other PI-based regimens in single PI-experienced, non-nucleoside reverse transcriptase inhibitor (NNRTI)-naive patients. In PI- and NNRTI-experienced patients, atazanavir/saquinavir was inferior to lopinavir/ritonavir; further well designed trials are required to determine the comparative efficacy of lopinavir/ritonavir versus other PIs such as ritonavir-boosted atazanavir, or fosamprenavir or tipranavir in these patients. Lopinavir/ritonavir is more likely than atazanavir (alone or boosted) or nelfinavir to cause hypertriglyceridaemia and is associated with a higher incidence of hypercholesterolaemia than atazanavir (alone or boosted). The new lopinavir/ritonavir tablet coformulation offers a reduced pill count and lack of food interaction, and ART-naive patients in the US and Canada, who are not receiving efavirenz, nelfinavir, nevirapine or amprenavir, may benefit from convenient once-daily administration of lopinavir/ritonavir. Thus, lopinavir/ritonavir is a convenient, effective option for use in the treatment of HIV infection in ART-naive and -experienced adults, adolescents and children.

Pharmacological Properties

Lopinavir is a potent, HIV-specific protease inhibitor. The pattern of primary mutations associated with resistance to the lopinavir/ritonavir coformulation has not been determined in ART-naive patients with HIV infection and there was no evidence of clinical resistance to lopinavir in viral isolates from ART-naive adults who received lopinavir/ritonavir 400mg/100mg for up to 7 years in three clinical studies. The incidence of cross-resistance to other PIs due to lopinavir/ritonavir treatment appears to be low.

The steady-state plasma lopinavir concentration at the end of the dose-administration period remained at least 51-fold above the lopinavir protein binding-adjusted 50% effective concentration after administration of lopinavir/ritonavir 800mg/200mg once daily and 400mg/100mg twice daily in ART-naive patients, and 400mg/100mg twice daily in ART-experienced patients with HIV infection. The rapid and extensive first-pass oxidative metabolism of lopinavir in the liver is mediated primarily by the cytochrome P450 (CYP)-3A4 and CYP3A5 isoenzymes; ritonavir inhibits the activity of CYP3A4 in a concentration-dependent manner in human liver microsomes resulting in increased plasma lopinavir concentrations after administration of coformulated lopinavir/ritonavir. The bioavailability of lopinavir is increased with concomitant administration of food with the capsule or liquid coformulations.

The capsule, liquid and tablet lopinavir/ritonavir coformulations are bioequivalent at a dose of lopinavir/ritonavir 400mg/100mg. Concomitant administration of food with the tablet coformulation does not produce a clinically significant effect on the bioavailability of lopinavir; the tablet coformulation may be administered with or without food. Induction or inhibition of the CYP isoenzymes results in a variety of interactions between lopinavir/ritonavir and other drugs.

Therapeutic Efficacy

The therapeutic efficacy of oral lopinavir/ritonavir in combination with other antiretroviral agents has been investigated in generally well designed trials in ART-naive and -experienced adults, adolescents and children with HIV infection.

Combination antiretroviral therapy with lopinavir/ritonavir effectively reduced viral load in ART-naive patients at both the 400mg/100mg twice-daily and 800mg/200mg once-daily dosages; viral load decreased to <50 copies/mL in at least 50% of ART-naive patients receiving either lopinavir/ritonavir dosage. Lopinavir/ritonavir 400mg/100mg twice daily was more likely than nelfinavir 750mg three times daily to produce sustained virological suppression. The antiviral efficacy of lopinavir/ritonavir-based therapy was maintained for up to 7 years.

In ART-naive or PI-experienced patients, a significantly better therapeutic response was achieved at week 48 with lopinavir/ritonavir- than saquinavir/ ritonavir-based therapy. In single PI-experienced, NNRTI-naive patients with virological failure, lopinavir/ritonavir-based therapy was significantly more effective than investigator-selected PI regimens containing saquinavir/ritonavir, indinavir/ritonavir, nelfinavir, indinavir, ritonavir, saquinavir and nelfinavir/saquinavir. In PI- and NNRTI-experienced patients, lopinavir/ritonavir produced a significantly better virological response than unboosted atazanavir and, in non-inferiority trials versus lopinavir/ritonavir, atazanavir plus ritonavir was non-inferior and atazanavir plus saquinavir was inferior; non-inferiority could not be established for fosamprenavir plus ritonavir. In HIV-infected children and adolescents, combination therapy with lopinavir/ritonavir produced a virological response at week 48 and this response was maintained for up to 72 weeks.

Tolerability

Lopinavir/ritonavir-containing regimens were generally well tolerated in clinical trials; the most common adverse events were gastrointestinal, including diarrhoea, nausea and vomiting, and were usually of mild to moderate severity. The incidence of diarrhoea appears to be dose-related. Serious adverse events related to lopinavir/ritonavir are rare. Lopinavir/ritonavir was also generally well tolerated in paediatric patients.

Except for a significantly higher incidence of diarrhoea with lopinavir/ ritonavir 400mg/100mg twice daily than with atazanavir plus ritonavir 300mg/ 100mg once-daily, lopinavir/ritonavir-based treatment was generally tolerated as well as or better than regimens containing atazanavir, atazanavir plus ritonavir or saquinavir, fosamprenavir plus ritonavir, nelfinavir or investigator-selected PIs. Lopinavir/ritonavir is more likely than atazanavir (alone or boosted) or nelfinavir to cause hypertriglyceridaemia and is associated with a higher incidence of hypercholesterolaemia than atazanavir (alone or boosted). Increased liver amino-transferase levels were observed in similar proportions of patients receiving antiretroviral therapy containing lopinavir/ritonavir and other PIs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1
Table IV
Table V
Table VI

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents April 7 2005 [online]. Available from URL: http://AIDSinfo.nih.gov [Accessed 2005 Feb 4]

  2. Gazzard B, on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Medicine 2005; 6 Suppl. 2: 1–61

    Article  PubMed  Google Scholar 

  3. The EACS Euroguidelines Group. European guidelines for the clinical management and treatment of HIV-infected adults in Europe. AIDS 2003 Jun; 17 Suppl. 2: S3–26

    Article  Google Scholar 

  4. FDA/Center for Drug Evaluation and Research. Drugs@FDA [online]. Available from URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda [Accessed 2005 Oct 25]

  5. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998; 42(12): 3218–24

    PubMed  CAS  Google Scholar 

  6. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003; 63(8): 769–802

    Article  PubMed  CAS  Google Scholar 

  7. Abbott Laboratories. Kaletra® (lopinavir/ritonavir) tablets and oral solution. Prescribing information, [online]. Available from URL: http://www.kaletra.com [Accessed 2005 Nov 15]

  8. Murphy RL, Bran S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviralnaive adults with HIV-1 infection: 48-week results. AIDS 2001 Jan 5; 15(1): F1–9

    Article  PubMed  CAS  Google Scholar 

  9. Molina JM, Wilkin A, Domingo P, et al. Once-daily vs twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 96-week results [abstract no. WePe12.3C12 plus poster]. Third International AIDS Society Conference on HIV Pathogenesis and Treatment; 2005 Jul 24–27; Rio de Janeiro

  10. King MS, Bernstein BM, Walmsley SL, et al. Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis 2004 Jul 15; 190(2): 280–4

    Article  PubMed  CAS  Google Scholar 

  11. Murphy R, Da Silva B, McMillan F, et al. Seven year follow-up of a lopinavir/ritonavir-based regimen in antiretroviral-naive subjects [abstract no. PE7.9/3 plus poster]. 10th European Aids Conference; 2005 Nov 17–20; Dublin

  12. Hicks C, da Silva B, Benson C, et al. Extensive resistance testing during 5 years of lopinavir/ritonavir treatment in antiretroviral-naive HIV infected patients: results from study m97-720 [abstract no. WeOrB1291 plus oral presentation]. 15th International AIDS Conference; 2004 Jul 11–16; Bangkok

  13. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004 Jan 1; 189(1): 51–60

    Article  PubMed  CAS  Google Scholar 

  14. King M, Lipman B, Molla A, et al. Assessing the potential for protease inhibitor cross-resistance in antiretroviral-naive patients experiencing viral rebound on a lopinavir/ritonavir-based regimen [abstract no. 9.9 plus poster]. 3rd European HIV Drug Resistance Workshop; 2005 30 Mar–1 Apr; Athens

  15. Molina JM, Gathe J, Lim PL, et al. Comprehensive resistance testing in antiretroviral naive patients treated with once-daily lopinavir/ritonavir plus tenofovir and emtricitabine: 48-week results from study 418 [abstract no. WePeB5701 plus poster]. 15th International AIDS Conference; 2004 Jul 11–16; Bangkok

  16. Saez-Llorens X, Violari A, Deetz CO, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003 Mar; 22: 216–23

    PubMed  Google Scholar 

  17. Kempf DJ, Isaacson JD, King MS, et al. Identification of genotypic changes in human immunodeficiency viras protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001 Aug; 75(16): 7462–9

    Article  PubMed  CAS  Google Scholar 

  18. Mo H, King MS, King K, et al. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J Virol 2005 Mar; 79(6): 3329–38

    Article  PubMed  CAS  Google Scholar 

  19. Delaugerre C, Teglas JP, Treluyer JM, et al. Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2004 Oct 1; 37(2): 1269–75

    Article  PubMed  CAS  Google Scholar 

  20. Kempf DJ, Isaacson JD, King MS, et al. Analysis of the virologic response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir. Antiviral Ther 2002 Sep; 7(3): 165–74

    CAS  Google Scholar 

  21. de Mendoza C, Martin-Carbonero L, Barreiro P, et al. Salvage treatment with lopinavir/ritonavir (Kaletra. HIV Clin Trials 2002 Jul–Aug; 3(4): 304–9

    Article  PubMed  Google Scholar 

  22. Yusa K, Harada S. Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro. Curr Pharm Design 2004; 10: 4055–64

    Article  CAS  Google Scholar 

  23. Parkin NT, Chappey C, Petropoulos CJ. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS 2003; 17: 955–61

    Article  PubMed  CAS  Google Scholar 

  24. Loutfy MR, Raboud JM, Walmsley SL, et al. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens. Antivir Ther 2004 Aug; 9(4): 595–602

    PubMed  CAS  Google Scholar 

  25. Eron J, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis 2004 Jan 15; 189(2): 265–72

    Article  PubMed  CAS  Google Scholar 

  26. Bertz R, Foit C, Ye X, et al. Pharmacokinetics of once-daily vs twice-daily Kaletra® (lopinavir/ritonavir) in HIV+ subjects [abstract no. 126]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24–28; Seattle (WA)

  27. Crommentuyn KML, Mulder JW, Mairahu ATA, et al. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients. Antiviral Ther 2004 Oct; 9(5): 779–85

    CAS  Google Scholar 

  28. Bertz R, Lam W, Bran S, et al. Multiple-dose pharmacokinetics (PK) of ABT-378/ritonavir (ABT-378/r) in HIV+ subject [abstract no. 327]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco (CA)

  29. Yilmaz A, Stahle L, Hagberg L, et al. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen. Scand J Infect Dis 2004; 36 (11–12): 823–8

    Article  Google Scholar 

  30. Gustavson L, Lam W, Bertz R, et al. Assessment of the bioequivalence and food effects for liquid and soft elastic capsule co-formulations of ABT-378/ritonavir (ABT-378/r) in healthy subjects [poster]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto (ON)

  31. Awni W, Chiu Y-L, Braun N, et al. Significantly reduced food effect and pharmacokinetic variability with a novel lopinavir/ ritonavir tablet formulation [poster]. Third International AIDS Society Conference on HIV Pathogenesis and Treatment; 2005 24–27 Jul; Rio de Janiero

  32. Abbott Laboratories. Kaletra® (lopinavir/ritonavir) capsules and oral solution. Product label information. Abbott Laboratories, North Chicago, IL [online]. Available from URL: http://www.kaletra.com [Accessed 2005 Sep 23]

  33. Kumar GN, Dykstra J, Roberts EM, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab Dispos 1999; 27(8): 902–8

    PubMed  CAS  Google Scholar 

  34. Kumar GN, Jayanti V, Lee RD, et al. Invitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification. Drug Metab Dispos 1999; 27(1): 86–91

    PubMed  CAS  Google Scholar 

  35. Kumar GN, Jayanti VK, Johnson MK, et al. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm Res 2004 Sep; 21(9): 1622–30

    Article  PubMed  CAS  Google Scholar 

  36. European Medicines Agency. Scientific discussion [online]. Available from URL: http://www.emea.eu.int [Accessed 2005 Oct 19]

  37. Bertz R, Chiu Y-L, Foit C, et al. Estimation of selective pressure by lopinavir/ritonavir vs nelfinavir by examination of terminal-phase pharmacokinetics at steady-state [abstract no. 6.1 plus poster]. 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004 Apr 1–3; Rome

  38. Zhu T, Chiu Y, Doan T, et al. New tablet formulation of lopinavir/ritonavir is bioequivalent to the capsule at a dose of 800/200mg [abstract no. H-1894 plus poster]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16–19; Washington, DC

  39. Mirochnick M, Stek A, Capparelli E, et al. Adequate lopinavir exposure achieved with a higher dose during the third trimester of pregnancy [abstract no. 710]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5–8; Denver (CO)

  40. Lyons F, Lechelt M, Magaya V, et al. Adequate trough lopinavir levels with standard dosing in pregnancy [abstract no. 709]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5–8; Denver (CO)

  41. Arribas J, Pulido F, Peng JZ, et al. Evaluation of the mulitple-dose pharmacokinetics of lopinavir/ritonavir in HIV and HCV co-infected subjects with mild or moderate hepatic insufficiency [abstract no. F2/6]. 9th European AIDS Conference and 1st EACS Resistance and Pharmacology Workshop; 2003 Oct 25–29; Warsaw

  42. Abbott Laboratories Limited. Kaletra® (lopinavir/ritonavir) soft capsules: summary of product characteristics [online]. Available from URL: http://emc.medicines.org [Accessed 2005 Oct14]

  43. Kumar GN, Rodrigues AD, Buko AM, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 423–31

    PubMed  CAS  Google Scholar 

  44. Stevens RC, Rapaport S, Maroldo-Connelly L, et al. Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir [letter]. J Acq Imm Defic Syn 2003 Aug 15; 33(5): 650–1

    Article  Google Scholar 

  45. McCance-Katz EF, Rainey PM, Friedland G, et al. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis 2003 Aug 15; 37(4): 476–82

    Article  PubMed  CAS  Google Scholar 

  46. Vogel M, Voigt E, Michaelis HC, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004 Jul; 10(7): 939–44

    Article  PubMed  Google Scholar 

  47. Jain AB, Venkataramanan R, Eghtesad B, et al. Effect of coadministered lopinavir and ritonavir (Kaletra®) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl 2003 Sep; 9(9): 954–60

    Article  PubMed  Google Scholar 

  48. Klein CE, Chiu YC, Beck K, et al. Lack of effect of acid reducing agents on the pharmacokinetics (PK) of lopinavir/ ritonavir (LPV/r) tablet formulation [abstract no. L-1003 plus poster]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5–8; Denver (CO)

  49. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002 Jun 27; 346(26): 2039–46

    Article  PubMed  CAS  Google Scholar 

  50. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005 Apr 29; 19(7): 685–94

    Article  PubMed  CAS  Google Scholar 

  51. Clotet B, Moreno S, Gonzalez Lahoz J, et al. Efficacy and safety results of lopinavir/r based HAART treatment in expanded access program in Spain through W24 [abstract no. 235 plus poster]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001 Oct 28–31; Athens

  52. Germinario A, di Luzio Paparatti U, Chevallier P, et al. Initial efficacy and safety results from the lopinavir/ritonavir (ABT-378/r) early access program in Italy [abstract no. P233 plus poster]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001 Oct 28–31; Athens

  53. Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency viras type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002 Mar 1; 185(5): 599–607

    Article  PubMed  CAS  Google Scholar 

  54. Gathe J, Podzamczer D, Johnson M, et al. Once-daily vs twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 48-week results [abstract no. 570]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8–11; San Francisco (CA)

  55. Landay A, da Silva B, King M, et al. Immunologic reconstitution through 6 years in antiretroviral-naive subjects treated with lopinavir/ritonavir (LPV/r) [abstract no. WePe167B04 plus poster]. Third International AIDS Society Conference on HIV Pathogenesis and Treatment; 2005 Jul 24–27; Rio de Janiero

  56. Hicks C, King MS, Gulick RA, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS 2004 Mar 26; 18(5): 775–9

    Article  PubMed  CAS  Google Scholar 

  57. Eron J, Da Silva B, King M, et al. Lopinavir/ritonavir in antiretroviral-naive HIV-infected patients: 5-year follow-up [abstract no. H-844 plus oral presentation]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago (IL)

  58. Perrin L, King M, Bran S, et al. Failure to achieve HIV RNA <3 copies/ml does not predict loss of virologic response to Kaletra® (lopinavir/ritonavir) therapy through 3 years [abstract no. I-1927]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16–19; Chicago (IL)

  59. Ruane P, Mendonca J, Timerman A, et al. Kaletra® vs nelfinavir in antiretroviral-naive subjects: week 60 comparison in a phase III, blinded, randomized clinical trial [abstract no. 6 plus poster]. 1st International AIDS Society Conference; 2001 Jul 8–11;Bueno Aires, 80

  60. DeJesus E, LaMarca A, Sension M, et al. The CONTEXT Study: efficacy and safety of GW-433908/RTV in PI-experienced subjects with virological failure (24 week results) [abstract no. 178]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10–14; Boston (MA)

  61. Elston RC, Yates P, Tisdale M, et al. GW433908 (908)/ ritonavir: 48 week results in PI-experienced subjects: a retrospective analysis of virological response based on baseline genotype and phenotype [abstract no. MoOrB1055 plus oral presentation]. 15th International AIDS Conference; 2004 Jul 11–16; Bangkok

  62. Cooper D, Hicks C, Cahn P, et al. 24-Week RESIST Study analyses: the efficacy of tipranavir/ritonavir is superior to lopinavir/ritonavir, and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen [abstract no. 560]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22–25; Boston (MA)

  63. Cohen C, Nieto-Cisneros L, Zala C, et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res Opin 2005 Oct; 21(10): 1683–92

    Article  PubMed  CAS  Google Scholar 

  64. Pollard RB, Thompson M, Hicks M, et al. Phase 3 comparison of lopinavir/ritonavir vs investigator-selected protease inhibitors in single PI-experienced, NNRTI-naive patients: 48-week results of study M98-888 [abstract no. PI.3.2 plus poster]. 7th International Congress on Drug Therapy in HIV Infection; 2004 Nov 14–18; Glasgow

  65. Hicks C, for the RESIST-1 study team. Phase 3 comparison of TPV/r and standard-of-care boosted-comparator PI (CPI/r) at 24 weeks. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

  66. Cahn P, and the RESIST-2 study team. 24-week data from RESIST-2: phase 3 study of the efficacy and safety of background therapy plus tipranavir/ritonavir (TPV/r) or optimised ritonavir-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomised multicenter trial in treatment-experienced HIV+ patients [abstract no. PL 14.3]. 7th International Congress on Drug Therapy in HIV Infection; 2004 Nov 14–18; Glasgow

  67. Dragsted UB, Gerstoft J, Youle M, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antiviral Ther 2005; 10(6): 735–43

    CAS  Google Scholar 

  68. Tipranavir Review Team (HFD-530). Memorandum (to FDA Antiviral Advisory Committee Members/Guests) [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4139b1-01-fda.htm [Accessed 2005 Nov 2]

  69. Fischl M, Bassett R, Collier A, et al. Randomized, controlled trial of lopinavir/ritonavir + efavirenz vs efavirenz + 2 nucleo-side reverse transcriptase inhibitors following a first suppressive 3- or 4-drug regimen in advanced HIV disease [abstract no. 162]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22–25; Boston (MA)

  70. Cahn P, Renz C, Saez-Llorens X, et al. Kaletra® (ABT-378/ ritonavir) in HIV-infected children at 72 weeks [abstract no. 779 plus poster]. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment; 2001 Jul 8–11; Buenos Aires

  71. Bernstein B, King M, Brun S, et al. Safety of Kaletra®: data from phase II and phase III clinical trials [poster]. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment; 2001 Jul 8–11; Buenos Aires

  72. Montaner J, Canadian Kaletra Early Access Study Group. ABT-378/ritonavir: preliminary results of an early access program in Canada [abstract no. P230 plus poster]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001 Oct 28–31; Athens

  73. Rockstroh JK, Lohrengel B, Rode RA, et al. Efficacy and safety results from the ABT-378/R early access program in Germany [abstract no. P232 plus poster]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001 Oct 28–31; Athens

  74. Bongiovanni M, Cicconi P, Landonio S, et al. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. Int J Antimicrob Agents 2005 Jul; 26(1): 88–91

    Article  PubMed  CAS  Google Scholar 

  75. Lafeuillade A, Dupon M, Livrozet J-M, et al. Efficacy and tolerance of lopinavir/ritonavir in clinical practice: an observational prospective cohort of 1278 patients [poster]. 7th International Congress on Drug Therapy and HIV Infection; 2004 Nov 14–18; Glasgow

  76. Lafeuillade A, Hittinger G, Philip G, et al. Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra®). HIV Clin Trials 2004 Dec; 5(6): 392–8

    Article  PubMed  Google Scholar 

  77. Montes ML, Pulido F, Barros C, et al. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J Antimicrob Chemother 2005 May; 55(5): 800–4

    Article  PubMed  CAS  Google Scholar 

  78. Martinez E, Domingo P, Galindo MJ, et al. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis 2004 Apr 1; 38(7): 1017–23

    Article  PubMed  CAS  Google Scholar 

  79. Hayden R, Rode R, Mingrone H, et al. Evaluation of side effect tolerability and quality of life measures in patients after substitution of their PI/NNRTI with lopinavir/ritonavir [abstract no. 557 plus poster]. 2nd IAS Conference on HIV Pathogenesis and Treatment; 2003 Jul 13–16; Paris

  80. Luo MP, Shen Y, Rode R, et al. Substitution to lopinavir/ ritonavir is associated with improved patient-reported fatigue in HIV+ patients experiencing side effects related to their protease inhibitor non-nucleoside reverse transcriptase inhibitor [abstract no. PIN30]. Value Health 2004; 7(3): 360

    Article  Google Scholar 

  81. Shahriar J, Delate T, Hays RD, et al. Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease. Health and Qual Life Outcomes 2003; 1(1): 25–31

    Article  Google Scholar 

  82. Joshi M, Nowakowski K, Wehrle K, et al. The prevalence of lipid lowering agent use in HIV+ patients starting commonly used highly active antiretroviral therapies (HAART): a US-based national assessment [abstract no. 812]. 43rd Annual Meeting of IDSA (Infectous Diseases Society of America); 2005 Oct 6–9; San Francisco (CA)

  83. da Silva B, King M, Cernohous P, et al. Risk factors for body fat composition changes in patients treated with lopinavir/ ritonavir or nelfinavir [abstract no. 99 plus poster]. 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; 2003 Jul 8–11; Paris

  84. Luo MP, Boggs B, Bernstein B, et al. Cost-consequence comparison of lopinavir/ritonavir (LPV/r) vs. nelfinavir (NFV) therapy in treating antiretroviral naive HIV patients using clinical trial data [abstract no. PIN14]. Value Health 2002 Nov–Dec; 5(6): 566–7

    Google Scholar 

  85. Simpson KN, Luo MP, Chumney E, et al. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials 2004 Oct; 5(5): 294–304

    Article  PubMed  Google Scholar 

  86. Grover S, Coupal L, Lowensteyn I, et al. An economic analysis of the impact of highly active antiretroviral therapy associated dyslipidemia on cardiovascular risk and left expectancy [abstract no. 651]. Pharmacoepidemiol Drug Saf 2004 Jul; 13 Suppl. 1: 328

    Google Scholar 

  87. Simpson KN, Luo MP, Chumney E, et al. Cost effectiveness of lopinavir/ritonavir vs atazanavir in treating antiretroviral-naive patients: modeling the combined effects of HIV and heart disease [abstract no. P27]. 7th International Congress on Drug Therapy in HIV Infection; 2004 Nov 14–18; Glasgow

  88. Toward T, Scullard G, Pang F, et al. What is the cost of treating a typical HIV-centre patient cohort with either Kaletra® (LPV/ r)- or Reyataz (ATWRTV)-based regimen in the UK? [abstract no. PE19.2/1 plus poster]. 10th European AIDS Conference; 2005 Nov 17–20; Dublin

  89. Grimes RM, Helmy A. Cost and effectiveness of six recommended antiretroviral regimens used for initial treatment of HIV infected patients [abstract no. TuPeC4945 plus poster]. 15th International AIDS Conference; 2004 Jul 11–16; Bangkok

  90. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004 Jul 14; 292(2): 251–65

    Article  PubMed  CAS  Google Scholar 

  91. Swainston Harrison T, Scott LJ. Atazanavir: a review of its use in the management of HIV infection. Drugs 2005; 65(16): 2309–36

    Article  PubMed  Google Scholar 

  92. Moyle G. The APPT-1 study: assessing patients’ preferred treatments [abstract no. p99]. 6th International Congress on Drug Therapy in HIV Infection; 2002 Nov 17–21; Glasgow

  93. Heiser CR, Ernst JA, Barrett JT, et al. Probiotics, soluble fiber, and L-Glutamine (GLN) reduce nelfinavir (NFV)- or lopinavir/ritonavir (LPV/r)-related diarrhoea. J Int Assoc Physicians AIDS Care 2004; 3(4): 121–9

    Article  Google Scholar 

  94. Scott JD. Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients. Am J Health Syst Pharm 2005 Apr; 62: 809–15

    PubMed  CAS  Google Scholar 

  95. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection [online]. Available from URL: http://aidsinfo.nih.gov [Accessed 2005 Nov 1]

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Vicki Oldfield.

Additional information

Various sections of the manuscript reviewed by: M. Bongiovanni, Institute of Infectious and Tropical Diseases, University of Milan, Ospedale Luigi Sacco, Milan, Italy; J. Gathe, Therapeutic Concepts, Houston, Texas, USA; F. Gutiérrez, Infectious Diseases and HIV Unit, Hospital General Universitario de Elche, Elche, Spain; C. Hicks, Department of Medicine, Division of Infectious Diseases and International Health, Duke University Medical Centre, Durham, North Carolina, USA; M. Loutfy, Infectious Diseases, Toronto General Hospital, Toronto, Ontario, Canada; E. McCance-Katz, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia, USA; X. Sáez-Llorens, Hospital del Niño, Panama City, Panama; J.D. Scott, Western University of Health Sciences, Pomona, California, USA.

Data Selection

Soutces: Medical literature published in any language since 1980 on ‘lopinavir/ritonavir’, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: MEDLINE and EMBASE search terms were ‘lopinavir ritonavir’ in title. AdisBase search terms were ‘lopinavir/ritonavir’ or ‘lopinavir-ritonavir’ or ‘ABT-378/ritonavir’. Searches were last updated 10 May 2006.

Selection: Studies in patients with HIV infection who received lopinavir/ritonavir. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Lopinavir, ritonavir, HIV, pharmacodynamics, pharmacokinetics, drug interactions, therapeutic use, tolerability.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oldfield, V., Plosker, G.L. Lopinavir/Ritonavir. Drugs 66, 1275–1299 (2006). https://doi.org/10.2165/00003495-200666090-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666090-00012

Keywords

Navigation